The companies will continue with their exclusive agreements, including commercialization of their current portfolio
The company develops sustainable botanical materials for agricultural and pharmaceutical applications
The six-layer packaging ensures that external media such as bacteria, light and air do not contaminate the liquid
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Go-ahead for pivotal clinical trial which is expected to commence by March
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
The recommended daily dose for Ryaltris is 2 sprays in each nostril twice daily
Nuvaxovid is the first protein-based Covid-19 vaccine granted approval in South Korea
The product will be marketed under store brand labels and is comparable to the brand Zyrtec
Subscribe To Our Newsletter & Stay Updated
